Antibody for adcc and inducing cytokine production
CA 2498787 A1 · Owner: Lfb Biotechnologies · Inventors: Lirochon, Jacky; Bourel, Dominique; De Romeuf, Christophe
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns chimeric monoclonal antibodies humanized or human produced in selected cell lines said antibodies exhibiting high affinity for the CD16 receptor of effector cells of the immune system and hence capable of inducing high ADCC but also the property of inducing cytokine and interleukin secretion in particular IFN.gamma. which can enhance the ADCC activity of effector cells and hence be used for treating cancers and infections by pathogenic agents.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 15, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 15, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 15, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.